Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLDX logo CLDX
Upturn stock rating
CLDX logo

Celldex Therapeutics Inc (CLDX)

Upturn stock rating
$26.83
Last Close (24-hour delay)
Profit since last BUY6.47%
upturn advisory
Consider higher Upturn Star rating
BUY since 27 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

10/17/2025: CLDX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

14 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $53.85

1 Year Target Price $53.85

Analysts Price Target For last 52 week
$53.85 Target price
52w Low $14.4
Current$26.83
52w High $29.38

Analysis of Past Performance

Type Stock
Historic Profit -48.78%
Avg. Invested days 25
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulation Last Close 10/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.78B USD
Price to earnings Ratio -
1Y Target Price 53.85
Price to earnings Ratio -
1Y Target Price 53.85
Volume (30-day avg) 14
Beta 1.33
52 Weeks Range 14.40 - 29.38
Updated Date 10/18/2025
52 Weeks Range 14.40 - 29.38
Updated Date 10/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.01

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -8747.53%

Management Effectiveness

Return on Assets (TTM) -19.08%
Return on Equity (TTM) -27.18%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1089303162
Price to Sales(TTM) 307.72
Enterprise Value 1089303162
Price to Sales(TTM) 307.72
Enterprise Value to Revenue 188.14
Enterprise Value to EBITDA -17.34
Shares Outstanding 66406544
Shares Floating 53206915
Shares Outstanding 66406544
Shares Floating 53206915
Percent Insiders 0.19
Percent Institutions 111.25

ai summary icon Upturn AI SWOT

Celldex Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Celldex Therapeutics Inc. was founded in 1991. It is a biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer and other diseases. Over time, Celldex has evolved from a drug delivery company to a leader in antibody-based therapeutics.

business area logo Core Business Areas

  • Immunotherapy Development: Celldex focuses on developing antibody-based therapies that harness the body's immune system to fight cancer. These therapies target specific molecules on cancer cells to stimulate an immune response.
  • Proprietary Technology Platform: The company has a proprietary technology platform for identifying and developing novel antibodies and other immunotherapeutic agents.

leadership logo Leadership and Structure

Anthony Marucci is the Co-founder, President and Chief Executive Officer. The company has a typical structure of a publicly traded biopharmaceutical firm, with a board of directors and various departments (research, development, clinical, commercial, etc.).

Top Products and Market Share

overview logo Key Offerings

  • Varlilumab (anti-CD27 antibody): An investigational immunotherapy targeting the CD27 receptor to activate immune cells. It is currently in clinical trials for various cancers. Market share data is not applicable as it is not yet approved for sale. Competitors include companies developing similar immuno-oncology therapies (e.g., Merck (MRK) with Keytruda, Bristol Myers Squibb (BMY) with Opdivo).
  • CDX-0159 (anti-KIT antibody): An investigational immunotherapy targeting KIT, being developed for chronic urticaria. Market share data is not applicable as it is not yet approved for sale. Competitors in chronic urticaria include Novartis (NVS) and Genentech (Roche) with Xolair.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investments in research and development. Immunotherapy is a major area of focus, with many companies developing new therapies to treat cancer and other diseases.

Positioning

Celldex is a smaller player in the immunotherapy market, focusing on novel antibody-based therapies. Its competitive advantage lies in its proprietary technology platform and its focus on specific targets that are not yet widely addressed by other companies.

Total Addressable Market (TAM)

The total addressable market for cancer immunotherapy is estimated to be over $100 billion. Celldex is positioned to capture a portion of this market with its novel therapies, especially if varlilumab or CDX-0159 are approved. For chronic urticaria, market size for treatments are roughly 2 to 4 billion USD annually. Again, Celldex is positioned to capture a portion of this market

Upturn SWOT Analysis

Strengths

  • Proprietary technology platform
  • Focus on novel antibody-based therapies
  • Experienced management team
  • Strong pipeline of clinical-stage product candidates

Weaknesses

  • Reliance on clinical trial outcomes
  • Limited financial resources compared to larger pharmaceutical companies
  • Lack of approved products
  • High research and development costs

Opportunities

  • Positive clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • FDA approval of product candidates

Threats

  • Clinical trial failures
  • Competition from larger pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • BMY
  • NVS
  • ROSY

Competitive Landscape

Celldex faces intense competition from larger pharmaceutical companies with more resources. However, its focus on novel targets and its proprietary technology platform give it a competitive edge in certain areas.

Growth Trajectory and Initiatives

Historical Growth: The company's growth has been primarily driven by clinical trial progress and partnerships.

Future Projections: Future growth depends on the success of its clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived probability of success for their pipeline.

Recent Initiatives: Recent initiatives include advancing clinical trials for varlilumab and CDX-0159 and exploring new therapeutic targets.

Summary

Celldex Therapeutics is a development-stage company focused on novel immunotherapy. It shows promise through its proprietary tech and focused pipeline, particularly varlilumab and CDX-0159. However, it faces financial constraints and relies heavily on positive clinical trial outcomes. It needs to be nimble to compete with larger pharmaceutical companies. Any negative clinical trial results will put the company in a very weak position.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence. Market share data is estimated and may not be precise.

Upturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Celldex Therapeutics Inc

Exchange NASDAQ
Headquaters Hampton, NJ, United States
IPO Launch date 2008-03-10
Founder, President, CEO & Director Mr. Anthony S. Marucci M.B.A.
Sector Healthcare
Industry Biotechnology
Full time employees 186
Full time employees 186

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.